PM360
DECEMBER 14, 2023
Empowering patients with comprehensive information about their health and medical conditions is a critical step towards fostering their active involvement in healthcare decisions. By equipping them with knowledge, patients can make more informed choices and collaborate effectively with healthcare providers (HCPs), ultimately enhancing the quality of care they receive.
Fierce Pharma
DECEMBER 14, 2023
Pfizer’s $43 billion acquisition of Seagen is in the books, the company said on Thursda | It’s a done deal. Pfizer’s $43 billion acquisition of Seagen is in the books, as it becomes the largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for $63 billion in 2019. The buyout of the antibody-drug conjugate specialist has doubled Pfizer’s pipeline to 60 programs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MedCity News
DECEMBER 13, 2023
Health systems have been increasingly dropping MA contracts, saying that they cause their organizations to lose too much money and result in dangerous patient care delays. To mitigate this issue, experts think large MA plans need to delegate more utilization management duties to health systems rather than handling it themselves.
PharmExec
DECEMBER 13, 2023
Lisa Conte, founder, president, and CEO of Jaguar Health, discusses how a climb up Mount Kilimanjaro would vault her to her true career calling—and spark a decades-long quest to accelerate breakthroughs in plant-based pharmaceuticals and supportive care.
European Pharmaceutical Review
DECEMBER 11, 2023
Results from MaaT Pharma’s Early Access Program (EAP) for its microbiome-based therapy MaaT013, have demonstrated positive overall response and overall survival rates in European patients with graft-versus-host disease (GvHD). The findings were presented at the 2023 American Society of Hematology (ASH) Annual Meeting. MaaT013 is an off-the-shelf, pooled-donor, enema Microbiome Ecosystem Therapy TM.
Fierce Pharma
DECEMBER 13, 2023
Using Tuesday to announce good news—that its $43 billion acquisition of Seagen would be | Using Tuesday to announce good news—that its $43 billion acquisition of Seagen would be finalized on Thursday—Pfizer sandwiched its bad news, which came on Wednesday with its 2024 guidance. The company expects revenue to reach between $58.5 billion and $61.5 billion next year, coming up short of the analyst consensus of $63.2 billion, largely because of the plummeting demand for its COVID-19 products.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
PM360
DECEMBER 14, 2023
Survey any physician if they’ve been asked by a patient about a prescription weight loss medication and you’ll hear a resounding “yes.” The recent Sermo Barometer confirms that 89% of 300+ global practitioners have seen an increase in patients proactively requesting prescription weight loss medications. 1 I predict this number will only steadily increase.
European Pharmaceutical Review
DECEMBER 14, 2023
In the ever-evolving landscape of regulatory decisions, the quest for safeguarding public health remains paramount. Decisions to remove medicines from market are not taken lightly and are often based upon all evidence available to inform a benefit/risk balance. This evidence can come from a range of sources, such as randomised controlled trials (RCTs), observational studies, and spontaneous reporting.
Fierce Pharma
DECEMBER 12, 2023
Over the past several years, drug shortages have vexed doctors and patients on both sides of the Atlantic, prompting lawmakers and government agencies to take action in both Europe and the U.S. | Tuesday, the European Medicines Agency laid out a list of more than 300 critical generic drugs that could fall prey to future shortages. Inclusion in the list doesn’t mean a particular drug is likely to experience a shortage anytime soon, the EMA said.
MedCity News
DECEMBER 14, 2023
There are a lack of women at venture capital firms. This makes it difficult for women’s health startups focused on stigmatized conditions to get funding when pitching to those who don’t always have a good understanding, startups say.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
PharmExec
DECEMBER 14, 2023
A discussion of the current standard for diabetes care and how the importance of patient centricity, including addressing patient's mental health, are imperative to the future of the space.
European Pharmaceutical Review
DECEMBER 12, 2023
Yannis Morel, Executive Vice President of product portfolio strategy and business development of Innate Pharma SA, offers insight on engineering antibodies to develop antibody-based NK cell therapeutics. He discusses why NK cell therapy’s ability to generate ‘synthetic immunity’ in the body means this modality holds potential as an anti-cancer treatment.
Fierce Pharma
DECEMBER 15, 2023
About a year after Arcutis Biotherapeutics unveiled positive data on roflumilast foam at the European Academy of Dermatology and Venereology congress 2022, the company has clinched a second FDA OK. | About a year after Arcutis Biotherapeutics unveiled positive data on roflumilast foam at the European Academy of Dermatology and Venereology congress 2022, the company has clinched a second FDA OK.
MedCity News
DECEMBER 13, 2023
About eight in 10 employers think drug costs, high-cost claims and hospital prices are a “significant threat to affordability,” according to a new survey from National Alliance of Healthcare Purchaser Coalitions.
Advertiser: ZoomInfo
Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr
PharmExec
DECEMBER 12, 2023
While hurdles remain, home healthcare could deliver better patient-centered cancer care—providing improved outcomes, enhanced quality of life, and reduced strain on resources.
Pharmaceutical Technology
DECEMBER 11, 2023
Trends in sustainability and quality assurance were key themes discussed at the recent CPHI Europe 2023 meeting, although the data reveals a lack of implementation of sustainable solutions.
Fierce Pharma
DECEMBER 12, 2023
To complete its acquisition of Seagen, what did Pfizer need to do to satisfy antitrust concerns of the Federal Trade Commission? | By agreeing to donate royalties on its U.S. sales of bladder cancer drug Bavencio, Pfizer has received the go-ahead to finalize its $43 billion buyout of Seagen, the company said on Tuesday. Pfizer expects to close the merger on Thursday.
MedCity News
DECEMBER 13, 2023
Google introduced a new suite of healthcare-focused generative AI models designed to speed up workflows for clinicians and medical researchers. Health systems and medical research organizations, including HCA Healthcare and BenchSci, have been testing these models since April.
Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist
What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.
PharmExec
DECEMBER 11, 2023
Phase III trial to investigate novel individualized neoantigen therapy V940 (mRNA-4157) in combination with Keytruda (pembrolizumab) as an adjuvant treatment for patients with completely resected Stage II, IIIA, or IIIB non-small cell lung cancer.
European Pharmaceutical Review
DECEMBER 13, 2023
The European Commission, the Heads of Medicines Agencies (HMA) and the European Medicines Agency (EMA) have published the first Union list of critical medicines. The list contains more than 200 active substances that are considered “critical for healthcare systems” across the EU/EEA. Continuity of supply is seen as a priority for these substances and shortages should be avoided.
Fierce Pharma
DECEMBER 15, 2023
Since Merck secured approval for kidney cancer pill and blockbuster hopeful Welireg (belzutifan) in August of 2021, sales have grown slowly but surely. | Since Merck secured approval for kidney cancer pill and blockbuster hopeful Welireg (belzutifan) in August of 2021, sales have grown slowly but surely. With a second FDA nod for a much larger patient population, the company can anticipate a more pronounced upswing in revenue from the hypoxia-inducible factor-2 alpha (HIF-2a) inhibitor.
MedCity News
DECEMBER 12, 2023
Sanofi, which markets the two primary treatments for Pompe disease, was trying to add a third one by licensing rights to a Maze Therapeutics drug candidate with a different therapeutic approach. A Federal Trade Commission complaint alleges the deal amounts to a monopoly player taking out its competition.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
PharmExec
DECEMBER 12, 2023
Experts gauge whether the needle is finally moving on the effective structuring of outcomes centered payment agreements—from operational, technology, and acceptance standpoints.
European Pharmaceutical Review
DECEMBER 15, 2023
Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 (V940) in combination with MSD’s Keytruda in patients with resected high-risk melanoma. The randomised study, KEYNOTE-942, evaluated the treatment in patients with high-risk stage III/IV melanoma. Analysis shows that after three years, treatment with mRNA-4157 (V940) in combination with checkpoint inhibitor Keytruda reduced the risk of recurrence or death by 49 percent compared w
Fierce Pharma
DECEMBER 9, 2023
BCMA-targeted therapies are transforming care for multiple myeloma patients. But these immunotherapies also come with various potentially dangerous side effects. | A new study examined side effect reports of BMCA immunotherapies from the FDA Adverse Event Reporting System, hoping to help inform doctors in their treatment decisions.
MedCity News
DECEMBER 11, 2023
Fruit Street Health’s complaint alleged that Sharecare violated the terms of their shared business agreement by rolling out its own version of Fruit Street’s diabetes prevention program, which had been previously offered to Sharecare members. Sharecare said that the lawsuit is baseless.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
PharmExec
DECEMBER 14, 2023
JAMA Network study evaluates current attitudes toward individuals with acne with a call for pharma companies to focus efforts on helping to overcome these stigmas.
Pharmaceutical Technology
DECEMBER 13, 2023
Advanced simulation methods and tools are not only paving the way for more efficient manufacturing operations. At SHL Medical, they’re also speeding up the development of new production facilities around the globe.
Fierce Pharma
DECEMBER 12, 2023
As waves of layoffs continue to hit the biopharma industry, Ferring Pharmaceuticals is trimming its headcount by 134 across its two U.S. locations. | The drugmaker will lay off 79 at its New Jersey headquarters and 55 at its microbiome subsidiary Rebiotix in Minnesota as a result of a "revised business strategy.
MedCity News
DECEMBER 15, 2023
By prioritizing patient care and adapting our business models to meet the demands of our patients, we can ensure that the telehealth industry continues to provide meaningful and lasting benefits to all those who need it.
Advertiser: ZoomInfo
In times of economic uncertainty, account-based strategies are essential. According to several business analysts and practitioners, ABM is a necessity for creating more predictable revenue. Research shows that nearly three-quarters of marketers (74%) already have the resources needed to build successful ABM programs.
Expert insights. Personalized for you.
98 
Let's personalize your content